Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Open Posted
- Opportunity number
- PAR-25-103
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.399 Cancer Control
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Health
- Eligible applicants
-
- Small Businesses
- Independent School Districts
- State Governments
- For Profit Organizations
- City/Township Governments
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- 501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Special District Governments
- Public or Indian Housing Auth.
- Other
- County Governments
- Higher Education Inst. (Public)
- Tribal Organizations (Not Federally Recognized)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional) to fund preparatory studies that address information gaps before full-scale clinical trials, with an application due date of October 25, 2027. This cooperative agreement mechanism is open to a broad range of applicants including for-profit organizations, nonprofits (501(c)(3) and non-501(c)(3)), governmental entities, tribal governments and organizations, educational institutions (public and private), special district governments, and eligible faith-based or community-based organizations; applicants also include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, eligible federal agencies, regional organizations, non-domestic entities, and U.S. territories.
Funded projects must address critical unknowns in clinical trial design across the cancer prevention and control spectrum—including prevention and interception, health behaviors, screening, early detection, healthcare delivery, treatment-related symptom management, supportive care, and survivorship outcomes. Preparatory studies are expected to fill gaps regarding study population characteristics, accrual feasibility, intervention details, outcome endpoints, data and statistical challenges, and operational risks, thereby reducing protocol changes, timeline extensions, and costs while testing the feasibility of novel trial designs.
Applications will be evaluated on scientific and technical merit, investigator competency, adequacy of facilities and resources, budget necessity, and relevance to program objectives. The award falls under CFDA 93.399 (Cancer Control). No cost share is specified. Award amounts, expected number of awards, and period of performance details are not provided in the source material.
Synopsis
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-103-Full-Announcement.html | HTML file | |
| PKG00288473.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity